Faculty of Medicine and Health, University Health Care Research Centre, Örebro University, Örebro, Sweden.
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
JAMA Netw Open. 2024 Jul 1;7(7):e2422738. doi: 10.1001/jamanetworkopen.2024.22738.
Electroconvulsive therapy (ECT), wherein a generalized epileptic seizure is induced, is a treatment for major depressive disorder (MDD). Currently, it is unclear whether there is an association between seizure length and treatment outcome.
To explore the association between seizure duration, potential confounding variables, and ECT treatment outcome.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study obtained data from the Swedish National Quality Register for ECT. Patients treated for unipolar MDD with unilateral electrode placement between January 1, 2012, and December 31, 2019, were included. The electroencephalographic (EEG) seizure duration from the first ECT treatment session for each patient was used for analysis. Data analyses were performed between March 2021 and May 2024.
The primary outcome was remission, defined as a cutoff score of less than 10 points on the self-assessment version of the Montgomery-Åsberg Depression Rating Scale within 1 week after ECT. Multivariate logistic regression analysis was performed to calculate odds ratios (ORs) between different seizure duration groups. Furthermore, the associations between concomitant use of pharmacological treatments, seizure duration, and remission rate were explored.
Among the 6998 patients included, 4229 (60.4%) were female and the mean (SD) age was 55.2 (18.6) years. Overall, 2749 patients (39.3%) achieved remission after ECT. Patients with EEG seizure duration of 60 to 69 seconds had the highest remission rates compared with patients with seizure duration of less than 20 seconds (OR, 2.17; 95% CI, 1.63-2.88; P < .001). Anticonvulsant medications were associated with shorter seizure duration (eg, lamotrigine: β coefficient [SE], -6.02 [1.08]; P < .001) and lower remission rates (eg, lamotrigine: adjusted OR, 0.67; 95% CI, 0.53-0.84; P < .001).
This study found an association between seizure length and remission from MDD. Use of anticonvulsant medication during ECT was associated with shorter seizure duration and lower remission rates after ECT.
电痉挛疗法(ECT)通过诱导全身性癫痫发作来治疗重度抑郁症(MDD)。目前,尚不清楚癫痫发作持续时间与治疗结果之间是否存在关联。
探讨癫痫持续时间、潜在混杂变量与 ECT 治疗结果之间的关系。
设计、设置和参与者:这项基于人群的队列研究从瑞典 ECT 质量登记处获取数据。纳入了 2012 年 1 月 1 日至 2019 年 12 月 31 日期间接受单侧电极安置治疗单相 MDD 的患者。每位患者首次 ECT 治疗时的脑电图(EEG)癫痫发作持续时间用于分析。数据分析于 2021 年 3 月至 2024 年 5 月进行。
主要结局是缓解,定义为 ECT 后 1 周内自我评估的蒙哥马利-Åsberg 抑郁评定量表评分低于 10 分。采用多变量逻辑回归分析计算不同癫痫发作持续时间组之间的优势比(OR)。此外,还探讨了伴随药物治疗、癫痫发作持续时间与缓解率之间的关系。
在纳入的 6998 例患者中,4229 例(60.4%)为女性,平均(SD)年龄为 55.2(18.6)岁。总体而言,2749 例(39.3%)患者在 ECT 后缓解。与癫痫发作持续时间<20 秒的患者相比,60-69 秒的患者缓解率最高(OR,2.17;95%CI,1.63-2.88;P<0.001)。抗惊厥药物与癫痫发作持续时间缩短相关(例如,拉莫三嗪:β系数[SE],-6.02[1.08];P<0.001),缓解率降低(例如,拉莫三嗪:调整后的 OR,0.67;95%CI,0.53-0.84;P<0.001)。
本研究发现癫痫发作持续时间与 MDD 缓解之间存在关联。ECT 期间使用抗惊厥药物与癫痫发作持续时间缩短和 ECT 后缓解率降低相关。